U.K. patients

People with multiple sclerosis (MS) in the United Kingdom are less likely to be on disease-modifying treatments (DMTs) compared with MS patients in other countries in Europe, a new study reports. “We know that getting early treatment with disease-modifying MS therapies can improve long term health and wellbeing.

No, it wasn’t my good wife, Jane, suddenly insisting we just had to take a break. Spontaneity is no longer a question for me. We can only go somewhere that has both a hoist and a profiling bed. Never mind a Molift and a shower chair. It’s…

It was a moment of clarity. Unfortunately, my attempt at making a bright, clear consommé has for the moment turned into a muddled chowder! Even worse, it was writing this column that started it. I’ve written so often in this column about using my Molift assistive device for transfers…

The week started with a bang, albeit with a hint of underlying anxiety. Friends and former work colleagues gathered during the first days of spring to chat in my sun-lathered back garden in South London. COVID-19 lateral flow tests had all been passed. Previously, we’d spent years working together on…

In truth, my long, bad Friday started on Thursday afternoon at 5 p.m., although it seems wrong in the middle of a black, midwinter night to still call it afternoon. Still, if you live in Alaska, summer nights never even start! (OK, I’ll stop musing about the vagaries of Earth’s…

People with multiple sclerosis (MS) living in the U.K. are now eligible to receive one of three new treatments for COVID-19 that are meant to prevent serious disease in at-risk populations who tested positive for the virus. First available under this plan were Regeneron and Roche’s antibody-based therapy…